Zacks Investment Research on MSN
Pfizer (PFE) stock sinks as market gains: Here's why
In the latest trading session, Pfizer (PFE) closed at $23.72, marking a -2.47% move from the previous day. The stock trailed the S&P 500, which registered a daily gain of 0.72%. Meanwhile, the Dow ...
HSBC downgraded Pfizer Inc. PFE on Monday, citing that the company’s near-term re-rating prospects have weakened despite its ...
The British company is developing two ADCs against B7-H3 and HER2 using a novel payload it is betting can overcome resistance to other ADCs.
Futures are trading higher as we get ready to start the first full week of trading for the third quarter, as traders and ...
Discover 5 top Big Pharma stocks amid rising cancer, type 2 diabetes and IMIDs—dividend yields, earnings beats and why they ...
Four stocks on the S&P 500 pay out dividends of more than 6% -- not including a couple that are real estate investment trusts ...
A Congressional investigation is looking into whether drug trials in China that involved U.S. companies possibly took place ...
Noel Anderson, CSO at American Red Cross, Sirsij Peshin, CPO at Pfizer & Lauren Riley, CSO at United Airlines, on how ...
Brandon Capital will receive more than $300 million from the sale of Myricx, which is developing cancer-killing “biological ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results